Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | IP6K1 | Q92551 | 5/20 | 0.47 |
| ▸ | IP6K3 | Q96PC2 | 5/20 | 0.47 |
| ▸ | IP6K2 | Q9UHH9 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561176 | 0.88 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL5548740 | 0.82 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL5668301 | 0.82 | MAPT (0.47) | ALDH1A1SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL3549996 | 0.79 | IP6K1 (0.62) | ALDH1A1SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL6010178 | 0.77 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL1757999 | 0.73 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL13208416 | 0.73 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL29080634 | 0.72 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL6012040 | 0.70 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL25991593 | 0.70 | IP6K1 (0.81) | ALDH1A1SMN1; SMN2HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655654-B2 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-02 | — | — | US | disclosed |
| US-7511138-B2 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-31 | — | — | US | disclosed |
| US-20080027086-A1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | ANGIBAUD PATRICK R | 2008-01-31 | — | — | US | disclosed |
| EP-1497295-B1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2006-08-16 | — | — | EP | disclosed |
| US-20050148609-A1 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles of triazoles | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-07 | — | — | US | disclosed |
| EP-1497295-A1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003087101-A1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148609-A1 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles of triazoles | FNTA, FNTB, HCCS | ALDH1A1 1560/4885SMN1; SMN2 4885/4885HPGD 2155/4885 |
| US-20080027086-A1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | FNTA, FNTB, CYP7A1 | ALDH1A1 1696/4885SMN1; SMN2 4885/4885HPGD 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.